{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:23:46Z","timestamp":1770236626520,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01252-x","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:31:29Z","timestamp":1770190289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics in Pediatric Asthma: Controlling Symptoms, Maintaining Safety, and Improving Outcomes"],"prefix":"10.1007","volume":"26","author":[{"given":"Priya","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Anderson III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"1252_CR1","unstructured":"Centers for Disease Control and Prevention. Most Recent National Asthma Data. Published 2022. Available from: https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm"},{"issue":"1","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.chest.2020.03.003","volume":"158","author":"SJ Szefler","year":"2020","unstructured":"Szefler SJ, Fitzgerald DA. Airway inflammation and treatment in children with severe asthma: understanding phenotypes to improve clinical management. Chest. 2020;158(1):6\u201314. https:\/\/doi.org\/10.1016\/j.chest.2020.03.003.","journal-title":"Chest"},{"issue":"1","key":"1252_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2354","volume":"137","author":"LJ Akinbami","year":"2016","unstructured":"Akinbami LJ, Simon AE, Rossen LM. Changing trends in asthma prevalence among children. Pediatrics. 2016;137(1):e20152354. https:\/\/doi.org\/10.1542\/peds.2015-2354.","journal-title":"Pediatrics"},{"issue":"2","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373. https:\/\/doi.org\/10.1183\/09031936.00202013.","journal-title":"Eur Respir J"},{"issue":"10396","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(23)01561-6","volume":"402","author":"C Porsbjerg","year":"2023","unstructured":"Porsbjerg C, Mel\u00e9n E, Lehtim\u00e4ki L, Shaw D. Asthma in children and adolescents: assessment and treatment. Lancet. 2023;402(10396):1228\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(23)01561-6.","journal-title":"Lancet"},{"issue":"3","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jaip.2021.11.023","volume":"10","author":"LB Bacharier","year":"2022","unstructured":"Bacharier LB, Guilbert TW, Mauger DT, et al. Biologic therapy for asthma in children: current evidence and future directions. J Allergy Clin Immunol Pract. 2022;10(3):640\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2021.11.023.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1252_CR7","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention \u2013 2023 Update. Available from: https:\/\/ginasthma.org"},{"issue":"6","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","volume":"146","author":"National Asthma Education and Prevention Program Coordinating Committee","year":"2020","unstructured":"National Asthma Education and Prevention Program Coordinating Committee. 2020 Focused Updates to the Asthma Management Guidelines: a report from the National Heart, Lung, and Blood Institute. J Allergy Clin Immunol. 2020;146(6):1217\u201370. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","volume":"129","author":"J Oppenheimer","year":"2022","unstructured":"Oppenheimer J, Hoyte FCL, Phipatanakul W, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129(2):169\u201380. https:\/\/doi.org\/10.1016\/j.anai.2022.02.021.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371. https:\/\/doi.org\/10.1056\/NEJMra2032506.","journal-title":"N Engl J Med"},{"issue":"26","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","volume":"341","author":"H Milgrom","year":"1999","unstructured":"Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 1999;341(26):1966\u201373. https:\/\/doi.org\/10.1056\/NEJM199912233412603.","journal-title":"N Engl J Med"},{"issue":"6","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.jaci.2020.11.025","volume":"147","author":"LB Bacharier","year":"2021","unstructured":"Bacharier LB, Jackson DJ, Biagini Myers JM, et al. Mepolizumab in children with severe eosinophilic asthma. J Allergy Clin Immunol. 2021;147(6):2245-53.e10. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2213-2600(19)30242-2","volume":"7","author":"S Khatri","year":"2019","unstructured":"Khatri S, Moore W, Gibson PG, et al. Assessment of benralizumab for severe asthma in adolescents and adults. Lancet Respir Med. 2019;7(10):883\u201396. https:\/\/doi.org\/10.1016\/S2213-2600(19)30242-2.","journal-title":"Lancet Respir Med"},{"issue":"24","key":"1252_CR14","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2108780","volume":"385","author":"LB Bacharier","year":"2021","unstructured":"Bacharier LB, Guilbert TW, Mauger DT, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385(24):2230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2108780.","journal-title":"N Engl J Med"},{"issue":"19","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2034975.","journal-title":"N Engl J Med"},{"issue":"2","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184\u201390. https:\/\/doi.org\/10.1067\/mai.2001.117880.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","volume":"108","author":"H Milgrom","year":"2001","unstructured":"Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. https:\/\/doi.org\/10.1542\/peds.108.2.e36.","journal-title":"Pediatrics"},{"issue":"6","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","volume":"124","author":"B Lanier","year":"2009","unstructured":"Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210\u20136. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.021.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","volume":"364","author":"WW Busse","year":"2011","unstructured":"Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1009705.","journal-title":"N Engl J Med"},{"issue":"6","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","volume":"136","author":"SJ Teach","year":"2015","unstructured":"Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476\u201385. https:\/\/doi.org\/10.1016\/j.jaci.2015.09.008.","journal-title":"J Allergy Clin Immunol"},{"key":"1252_CR21","doi-asserted-by":"publisher","unstructured":"Nieto Garc\u00eda A, Davila I, Gimeno D\u00edaz de Atauri A, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma (ANCHORS). Pediatr Allergy Immunol. 2021;32(7):1475\u201384. https:\/\/doi.org\/10.1111\/pai.13518","DOI":"10.1111\/pai.13518"},{"issue":"2","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","volume":"124","author":"WW Busse","year":"2020","unstructured":"Busse WW, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020;124(2):190\u20136. https:\/\/doi.org\/10.1016\/j.anai.2019.11.016.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1252_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100639","volume":"15","author":"NA Hanania","year":"2022","unstructured":"Hanania NA, Niven R, Chanez P, et al. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organ J. 2022;15(3):100639. https:\/\/doi.org\/10.1016\/j.waojou.2022.100639.","journal-title":"World Allergy Organ J"},{"issue":"3","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"2102662","DOI":"10.1183\/13993003.02662-2021","volume":"60","author":"M Humbert","year":"2022","unstructured":"Humbert M, Bousquet J, Pipet A, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60(3):2102662. https:\/\/doi.org\/10.1183\/13993003.02662-2021.","journal-title":"Eur Respir J"},{"issue":"1","key":"1252_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-6-32","volume":"6","author":"HL Kim","year":"2010","unstructured":"Kim HL, Leigh R, Becker A. Omalizumab: practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol. 2010;6(1):32. https:\/\/doi.org\/10.1186\/1710-1492-6-32.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"13","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, MENSA Investigators, et al. Mepolizumab treatment in patients with severe eosinophilic asthma MENSA Investigators. N Engl J Med. 2014;371(13):1198\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa1403290.","journal-title":"N Engl J Med"},{"issue":"13","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, SIRIUS Investigators, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma SIRIUS Investigators. N Engl J Med. 2014;371(13):1189\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1403291.","journal-title":"N Engl J Med"},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13223-019-0374-0","volume":"15","author":"SW Yancey","year":"2019","unstructured":"Yancey SW, Ortega HG, Keene ON, Bradford ES. Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy Asthma Clin Immunol. 2019;15:53. https:\/\/doi.org\/10.1186\/s13223-019-0374-0.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2019.07.013","volume":"144","author":"A Gupta","year":"2019","unstructured":"Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336-42.e7. https:\/\/doi.org\/10.1016\/j.jaci.2019.07.013.","journal-title":"J Allergy Clin Immunol"},{"key":"1252_CR30","doi-asserted-by":"publisher","unstructured":"Jackson DJ, Bacharier LB, Mauger DT, et al; Inner-City Asthma Consortium. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10353):502\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(22)01294-1","DOI":"10.1016\/S0140-6736(22)01294-1"},{"issue":"5","key":"1252_CR31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-054270","volume":"148","author":"HH De Keyser","year":"2021","unstructured":"De Keyser HH, Chipps B, Dinakar C. Biologics for asthma and allergic skin diseases in children. Pediatrics. 2021;148(5):e2021054270. https:\/\/doi.org\/10.1542\/peds.2021-054270.","journal-title":"Pediatrics"},{"issue":"3","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaci.2022.12.016","volume":"151","author":"LB Bacharier","year":"2023","unstructured":"Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023;151(3):581\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.016.","journal-title":"J Allergy Clin Immunol"},{"issue":"10056","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, investigators, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial investigators. Lancet. 2016;388(10056):2115\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1.","journal-title":"Lancet"},{"issue":"10056","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, CALIMA study investigators, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial CALIMA study investigators. Lancet. 2016;388(10056):2128\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8.","journal-title":"Lancet"},{"key":"1252_CR35","doi-asserted-by":"publisher","unstructured":"Wedner HJ, Fujisawa T, et al; TATE investigators. Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study). Pediatr Allergy Immunol. 2024;35(2):e14219. https:\/\/doi.org\/10.1111\/pai.14219","DOI":"10.1111\/pai.14219"},{"issue":"26","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"issue":"9","key":"1252_CR37","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1111\/all.14856","volume":"76","author":"JF Maspero","year":"2021","unstructured":"Maspero JF, Katelaris C, Busse WW, et al. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021;76(9):2621\u201334. https:\/\/doi.org\/10.1111\/all.14856.","journal-title":"Allergy"},{"issue":"6","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"2202095","DOI":"10.1183\/13993003.02095-2022","volume":"61","author":"AG Fiocchi","year":"2023","unstructured":"Fiocchi AG, Phipatanakul W, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023;61(6):2202095. https:\/\/doi.org\/10.1183\/13993003.02095-2022.","journal-title":"Eur Respir J"},{"issue":"3","key":"1252_CR39","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jaip.2023.10.012","volume":"12","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Hamelmann E, et al. Dupilumab efficacy and safety in children with moderate to severe asthma and high blood eosinophils: a post hoc analysis of VOYAGE. J Allergy Clin Immunol Pract. 2024;12(3):898-907.e7. https:\/\/doi.org\/10.1016\/j.jaip.2023.10.012.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1252_CR40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jaip.2024.01.014","volume":"12","author":"JF Maspero","year":"2024","unstructured":"Maspero JF, Antila MA, et al. Dupilumab efficacy in children with type 2 asthma receiving high- to medium-dose inhaled corticosteroids (VOYAGE). J Allergy Clin Immunol Pract. 2024;12(5):1271-80.e2. https:\/\/doi.org\/10.1016\/j.jaip.2024.01.014.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"1252_CR41","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1111\/all.15836","volume":"78","author":"NG Papadopoulos","year":"2023","unstructured":"Papadopoulos NG, Szefler SJ, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(10):2692\u2013703. https:\/\/doi.org\/10.1111\/all.15836.","journal-title":"Allergy"},{"issue":"5","key":"1252_CR42","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/ppul.26874","volume":"59","author":"W Phipatanakul","year":"2024","unstructured":"Phipatanakul W, Vogelberg C, et al. Dupilumab 200 mg was efficacious in children (6\u201311 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study. Pediatr Pulmonol. 2024;59(5):1221\u201332. https:\/\/doi.org\/10.1002\/ppul.26874.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"1252_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","volume":"133","author":"JA Lieberman","year":"2024","unstructured":"Lieberman JA, Chu DK, Ahmed T, et al. A systematic review and expert Delphi consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024;133(3):286\u201394. https:\/\/doi.org\/10.1016\/j.anai.2024.05.014.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1252_CR44","doi-asserted-by":"publisher","first-page":"12345","DOI":"10.1038\/s41598-025-12345-y","volume":"15","author":"H Gao","year":"2025","unstructured":"Gao H, Cao L, Liu C. Analysis and mining of dupilumab adverse events based on FAERS database. Sci Rep. 2025;15:12345. https:\/\/doi.org\/10.1038\/s41598-025-12345-y.","journal-title":"Sci Rep"},{"issue":"6","key":"1252_CR45","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/all.15197","volume":"77","author":"J Corren","year":"2022","unstructured":"Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786\u201396. https:\/\/doi.org\/10.1111\/all.15197.","journal-title":"Allergy"},{"issue":"1","key":"1252_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.anai.2022.08.009","volume":"130","author":"ID Pavord","year":"2023","unstructured":"Pavord ID, Hoyte FCL, Lindsley AW, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2023;130(1):59-67.e3. https:\/\/doi.org\/10.1016\/j.anai.2022.08.009.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1252_CR47","doi-asserted-by":"publisher","unstructured":"Menzies-Gow A, Wechsler ME, et al; DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11(6):524\u201337. https:\/\/doi.org\/10.1016\/S2213-2600(23)00067-4","DOI":"10.1016\/S2213-2600(23)00067-4"},{"issue":"1","key":"1252_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202206-0985OC","volume":"207","author":"J Corren","year":"2023","unstructured":"Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;207(1):13\u201323. https:\/\/doi.org\/10.1164\/rccm.202206-0985OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1252_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000536784","volume":"185","author":"J Lin","year":"2024","unstructured":"Lin J, Yang K, et al. Advanced biologic therapies in the management of asthma in children and adolescents: a comprehensive network meta-analysis. Int Arch Allergy Immunol. 2024;185(3):253\u201366. https:\/\/doi.org\/10.1159\/000536784.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"1252_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaci.2023.08.030","volume":"153","author":"E Bleecker","year":"2024","unstructured":"Bleecker E, Blaiss M, Jacob-Nara J, et al. Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study. J Allergy Clin Immunol. 2024;153(1):174\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030.","journal-title":"J Allergy Clin Immunol"},{"key":"1252_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2025.102375","volume":"90","author":"EO Okwuofu","year":"2025","unstructured":"Okwuofu EO, Yong ACH, Lim JCW, Stanslas J. The era of multiple biologics: is combination and switching an option in the management of severe asthma? Pulm Pharmacol Ther. 2025;90:102375. https:\/\/doi.org\/10.1016\/j.pupt.2025.102375.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"1252_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ajd.13676","volume":"62","author":"PD Mahar","year":"2021","unstructured":"Mahar PD, Zubrinich CM, Manuelpillai N, Foley P. Combination treatment with monoclonal antibodies: secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. Australas J Dermatol. 2021;62(4):506\u20138. https:\/\/doi.org\/10.1111\/ajd.13676.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1252_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(15)00042-9.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"1252_CR54","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1703574","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Castro M, O\u2019Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. N Engl J Med. 2017;377(10):936\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1703574.","journal-title":"N Engl J Med"},{"key":"1252_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jaip.2013.01.011","volume":"1","author":"CA Sorkness","year":"2013","unstructured":"Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1:163\u201371.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"1252_CR56","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/ppul.26027","volume":"57","author":"LB Bacharier","year":"2022","unstructured":"Bacharier LB. Biologic therapies for severe asthma in school-age children. Pediatr Pulmonol. 2022;57(9):2027\u201336. https:\/\/doi.org\/10.1002\/ppul.26027.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"1252_CR57","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jaci.2023.12.005","volume":"153","author":"GE Wilson","year":"2024","unstructured":"Wilson GE, Bacharier LB, et al. Activated sputum eosinophils associated with exacerbations in children on mepolizumab: follow-up from MUPPITS-2. J Allergy Clin Immunol. 2024;153(4):1231\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.005.","journal-title":"J Allergy Clin Immunol"},{"key":"1252_CR58","unstructured":"Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Available fromhttps:\/\/ginasthma.org"},{"issue":"3","key":"1252_CR59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MCP.0000000000001067","volume":"30","author":"A Mohan","year":"2024","unstructured":"Mohan A, Qiu AY, Lugogo N. Long-term safety, durability of response, cessation and switching of biologics. Curr Opin Pulm Med. 2024;30(3):303\u201312. https:\/\/doi.org\/10.1097\/MCP.0000000000001067.","journal-title":"Curr Opin Pulm Med"},{"key":"1252_CR60","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/JAA.S425199","volume":"16","author":"T Onalan","year":"2023","unstructured":"Onalan T, Colkesen F, Akkus FA, et al. Biologic treatment discontinuation in severe asthma: a real-life study on factors influencing clinical remission and physician decision-making. J Asthma Allergy. 2023;16:1205\u201316. https:\/\/doi.org\/10.2147\/JAA.S425199.","journal-title":"J Asthma Allergy"},{"issue":"7","key":"1252_CR61","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","volume":"9","author":"MM Jeffery","year":"2021","unstructured":"Jeffery MM, Inselman JW, Maddux JT, Rank MA, Shah ND, Ross JS, et al. Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics. J Allergy Clin Immunol Pract. 2021;9(7):2742-50.e1. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.031.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"1252_CR62","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/ppul.27218","volume":"59","author":"K Hillson","year":"2024","unstructured":"Hillson K, Saglani S, Bush A. The new biologic drugs: which children with asthma should get what? Pediatr Pulmonol. 2024;59(12):3057\u201374. https:\/\/doi.org\/10.1002\/ppul.27218.","journal-title":"Pediatr Pulmonol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:31:31Z","timestamp":1770190291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01252-x","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Chopra has no disclosures. Dr. Anderson has served as a consultant for Regeneron and Sanofi. He has received program development support from the Colorado Medicaid Supplement Funding Program.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"8"}}